TY - JOUR
T1 - Fluorescence-guided surgery of retroperitoneal-implanted human fibrosarcoma in nude mice delays or eliminates tumor recurrence and increases survival compared to bright-light surgery
AU - Uehara, Fuminari
AU - Hiroshima, Yukihiko
AU - Miwa, Shinji
AU - Tome, Yasunori
AU - Yano, Shuya
AU - Yamamoto, Mako
AU - Matsumoto, Yasunori
AU - Maehara, Hiroki
AU - Tanaka, Kazuhiro
AU - Bouvet, Michael
AU - Kanaya, Fuminori
AU - Hoffman, Robert M.
N1 - Publisher Copyright:
© 2015 Uehara et al.
PY - 2015/2/24
Y1 - 2015/2/24
N2 - The aim of this study is to determine if fluorescence-guided surgery (FGS) can eradicate human fibrosarcoma growing in the retroperitoneum of nude mice. One week after retroperitoneal implantation of human HT1080 fibrosarcoma cells, expressing green fluorescent protein (GFP) (HT-1080-GFP), in nudemice, bright-light surgery (BLS) was performed on all tumor-bearing mice (n = 22). After BLS,mice were randomized into 2 treatment groups; BLS-only (n = 11) or the combination of BLS + FGS (n = 11). The residual tumors remaining after BLS were resected with FGS using a hand-held portable imaging systemunder fluorescence navigation. The average residual tumor area after BLS + FGS was significantly smaller than after BLS-only (0.4 ± 0.4 mm2 and 10.5 ± 2.4 mm2, respectively; p = 0.006). Five weeks after surgery, the fluorescent-tumor areas of BLS- and BLS + FGS-treated mice were 379 ± 147 mm2and 11.7 ± 6.9 mm2, respectively, indicating that FGS greatly inhibited tumor recurrence compared to BLS. The combination of BLS + FGS significantly decreased fibrosarcoma recurrence compared to BLS-only treated mice (p < 0.001). Mice treated with BLS+FGS had a significantly higher disease-free survival rate than mice treated with BLS-only at five weeks after surgery. These results suggest that combination of BLS + FGS significantly reduced the residual fibrosarcoma volume after BLS and improved disease-free survival.
AB - The aim of this study is to determine if fluorescence-guided surgery (FGS) can eradicate human fibrosarcoma growing in the retroperitoneum of nude mice. One week after retroperitoneal implantation of human HT1080 fibrosarcoma cells, expressing green fluorescent protein (GFP) (HT-1080-GFP), in nudemice, bright-light surgery (BLS) was performed on all tumor-bearing mice (n = 22). After BLS,mice were randomized into 2 treatment groups; BLS-only (n = 11) or the combination of BLS + FGS (n = 11). The residual tumors remaining after BLS were resected with FGS using a hand-held portable imaging systemunder fluorescence navigation. The average residual tumor area after BLS + FGS was significantly smaller than after BLS-only (0.4 ± 0.4 mm2 and 10.5 ± 2.4 mm2, respectively; p = 0.006). Five weeks after surgery, the fluorescent-tumor areas of BLS- and BLS + FGS-treated mice were 379 ± 147 mm2and 11.7 ± 6.9 mm2, respectively, indicating that FGS greatly inhibited tumor recurrence compared to BLS. The combination of BLS + FGS significantly decreased fibrosarcoma recurrence compared to BLS-only treated mice (p < 0.001). Mice treated with BLS+FGS had a significantly higher disease-free survival rate than mice treated with BLS-only at five weeks after surgery. These results suggest that combination of BLS + FGS significantly reduced the residual fibrosarcoma volume after BLS and improved disease-free survival.
UR - http://www.scopus.com/inward/record.url?scp=84923617769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923617769&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0116865
DO - 10.1371/journal.pone.0116865
M3 - Article
C2 - 25710463
AN - SCOPUS:84923617769
SN - 1932-6203
VL - 10
JO - PLoS One
JF - PLoS One
IS - 2
M1 - e0116865
ER -
